Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

Curocell launches Limcato, South Koreas first domestic CAR-T cancer therapy Curocell introduces first local CAR-T therapy, ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...

The Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few months after it was given the okay south of the border. Yescarta ...

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape.Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - ...

INR:2188. wataru endō Yescarta trial data for high-risk lymphoma: complete remission rate exceeds 70% Red dot in gray: Biogen plans to submit BLA application for Ad ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor (CAR) T-cell therapies for the potential risk for secondary T-cell ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Gaza’s health ministry said that 88 people had been killed over the past day. Israeli and Hamas officials have been holding indirect cease-fire talks via mediators in Qatar. By Hiba Yazbek and ...

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...